Resource Summary Report

Generated by dkNET on Sep 9, 2026

PerCP anti-human CD45

RRID:AB_2566358
Type: Antibody

Proper Citation

BioLegend Cat# 368506, RRID:AB_2566358

Antibody Information

URL: http://antibodyregistry.org/AB_2566358

Proper Citation: BioLegend Cat# 368506, RRID:AB_2566358

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone 2D1

Antibody ID: AB_2566358

Vendor: BioLegend

Catalog Number: 368506

Alternative Catalog Numbers: 368505

Record Creation Time: 20231110T035153+0000

Record Last Update: 20260901T005354+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-human CD45.

No alerts have been found for PerCP anti-human CD45.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer cell.

Sprooten J, et al. (2024) Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. Cell reports. Medicine, 5(1), 101377.

de Cevins C, et al. (2023) Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response. Cell reports. Medicine, 4(12), 101333.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell reports, 38(2), 110235.

Janssen JJE, et al. (2022) Extracellular flux analyses reveal differences in mitochondrial PBMC metabolism between high-fit and low-fit females. American journal of physiology. Endocrinology and metabolism, 322(2), E141.

Kreutmair S, et al. (2021) Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity, 54(7), 1578.

Baliu-Piqué M, et al. (2021) Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT. eLife, 10.

Mulfaul K, et al. (2020) Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration. Cell reports, 30(7), 2209.